The latest price of acotinib in 2024

Acalabrutinib (Acalabrutinib) is an oral small molecule targeted drug that belongs to a class of drugs called "brutinib inhibitors". It is primarily used to treat a rare but serious blood cancer called adult chronic lymphocytic leukemia (CLL) and the similar adult B-cell non-Hodgkin lymphoma (NHL).

Acotinib is currently on the market in China and has been included in medical insurance. Patients can purchase it domestically, but the price is high, about 50,000 yuan. Please consult the local hospital pharmacy for specific prices and medical insurance reimbursement. The cheaper foreign generics of acotinib are mainly Laos and Bangladeshi generics. The Laos generics cost more than 3,000 yuan, and the Bangladeshi generics cost about 6,000 yuan. They are much cheaper than the domestic original drugs, and the ingredients of the original drugs and generic drugs are basically the same.

Acotinib specifically inhibits a key enzyme in the B cell receptor signaling pathway, namely Brutontyrosine kinase (BTK). This signaling pathway plays an important role in the survival, proliferation and invasion of cancer cells. By blocking BTK, acotinib can interfere with the growth of cancer cells and promote their death to a certain extent, thereby inhibiting the development of cancer.

Compared with some other similar drugs, acotinib is highly selective, i.e., it targets BTK more specifically, thereby reducing adverse effects on other cells and reducing the possibility of side effects. In addition, it exhibits better oral bioavailability, making treatment more convenient for patients.

In clinical trials, acotinib has shown efficacy in adults with chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. It has been shown to significantly extend patients' progression-free survival, improve symptoms and increase survival rates. Therefore, acotinib is considered an effective treatment option, especially for patients who are refractory to or intolerant to conventional treatments.